July 12, 2008 |
Amgen Inc. will pay Johnson & Johnson $200 million to settle an antitrust claim over discounts on Amgen's drugs for cancer patients, the companies said. Amgen, based in Thousand Oaks, admitted no liability in agreeing to pay the money to Ortho Biotech Products, a unit of Johnson & Johnson that accused Amgen of offering oncology clinics package discounts on their purchases of Aranesp, Neupogen and Neulasta.
April 1, 2008 |
Amgen Inc. and Johnson & Johnson have been asked to hand over to U.S. lawmakers documents related to the promotion of anemia drugs linked to increased risk of death at high doses. The documents, including records on direct-to-consumer television and print advertising, are sought by the House Committee on Energy and Commerce, led by John D. Dingell (D-Mich.), according to letters posted on the committee's website. The committee asked Johnson & Johnson to provide information on its ad campaigns for its anemia drug Procrit.
March 14, 2008 |
In mixed news for biotech giant Amgen Inc., a Food and Drug Administration panel recommended Thursday that doctors continue to prescribe the company's lucrative anemia drugs for patients with cancer. But the panel suggested scaling back which patients should be treated based on their type of cancer and the severity of the disease. The recommendations could lead to further sales declines in the company's blockbuster drug Aranesp. Thousand Oaks-based Amgen makes an identical product that is sold under the name Procrit by Johnson & Johnson.
March 8, 2008 |
Drug maker Amgen Inc. said regulators had added new warnings about the risks of death and tumor growth to the Thousand Oaks company's blockbuster anemia drugs. The warnings approved by the Food and Drug Administration say that Aranesp and Epogen increased the likelihood of death and accelerated tumor growth in patients with several types of cancer, including breast and cervical. The warnings also apply to Johnson & Johnson's drug Procrit.
November 30, 2007 |
Johnson & Johnson said it would take a $440-million charge on a write-down of assets related to Natrecor, a heart-failure treatment. The New Brunswick, N.J., drug maker is writing down Natrecor assets because of a recent decline in sales, according to the filing.
November 17, 2007 |
Johnson & Johnson's allergy treatment Zyrtec-D was approved by the Food and Drug Administration for sale without a prescription. The nonprescription form of the drug, which will be available in January, is expected to cost as much as a third less than prescription Zyrtec.
November 16, 2007 |
Healthcare products maker Johnson & Johnson, faced with lagging sales of some top products, said it would create three new units to boost prospects. The New Brunswick, N.J.-based company said it would create an office of strategy and growth to identify new opportunities, a surgical care group to focus on technology and services to improve patient care, and a comprehensive care group aimed at treatments for chronic and pervasive conditions.
November 9, 2007 |
Warning labels on anemia drugs made by Amgen Inc. and Johnson & Johnson have been strengthened to reflect concerns that they boost the risk of heart attacks, stroke and death, regulators said Thursday. Millions of cancer and kidney disease patients take the drugs, known as erythropoiesis-stimulating agents. EPO drugs include Amgen's biggest drug, Aranesp, and an older version, Epogen, and J&J's Procrit.
October 23, 2007 |
The largest group of U.S. cancer doctors said Monday that Medicare has gone too far in restricting the use of anemia drugs made by Amgen Inc. and Johnson & Johnson and released its own guidelines. The doctors' recommendations add new warnings about heart risks while saying patients can safely use higher doses than Medicare allows.
October 17, 2007 |
Amgen Inc. and Johnson & Johnson were set back in efforts to overturn Medicare limits on use of the firms' anemia drugs when U.S. drug regulators found the restrictions appropriate. Payment rules set by Medicare, the U.S. healthcare program for the elderly and disabled, are "generally consistent" with prescribing information for use of the drugs in cancer patients, the Food and Drug Administration said in a letter released Tuesday by Reps. Pete Stark (D-Fremont) and Henry A.